Efficiency and Security of NIVOLUMAB Therapy in Obese Individuals With COVID-19(COrona VIrus Disease) Infection

Exclusion Criteria

• •CRITERIA LINKED TO THE DISEASE SEVERITY :
• •* Patients hospitalized in ICU or constant care unit.
• •* Patients with clinical symptoms requiring ICU admission (respiratory rate\>30/min, oxygen requirement\> 4Liters/min (using high concentration mask) to reach and maintain O2saturation\>90%, qSOFA≥ 2(quick score of Sepsis-related Organ Failure Assessment), or associated multi-visceral failure.
• •* Patients with high biological probability of macrophage activation syndrome (hemoglobin \< 9.2 g/dl AND a blood platelets \< 110000/mm3 AND AST \> 30 U/l AND ferritin \> 600 mg/l).
• •CRITERIA LINKED TO THE TREATMENT TOXICITY :
• •Patients currently treated for cancer or with personal history of cancer within the last 3 years.
• •Patients with Chronic Obstructive Pulmonary Disease (COPD) (GOLD 3 and 4 stages).
• •Chronic respiratory insufficiency treated with oxygen.
• •Patients aged above 70 years old.
• •Active smoking.
• •Personal history of thoracic radiotherapy.
• •Patients with known sensibility to NIVOLUMAB or one of its component.
• •Patients upon immunosuppressive dosage of corticoids.
• •Patients upon immunosuppressive therapy or immunosuppressed patients.
• •Patients already presenting severe autoimmune disease, for whom additional immunologic activation response would potentially precipitate lethal prognosis
• •GENERAL CRITERIA:
• •Minor Patients
• •Mentally unbalanced patients, under supervision or guardianship,
• •Patient deprived of liberty,
• •Patient who does not understand French/ is unable to give consent,
• •Patient already included in a trial who may interfere with the study or in a period of exclusion following participation in a previous study.
• •Pregnant (controlled by a pregnancy test) or lactating woman